These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 33208882)

  • 21. Comprehensive study of nine novel cases of TFEB-amplified renal cell carcinoma: an aggressive tumour with frequent PDL1 expression.
    Kammerer-Jacquet SF; Gandon C; Dugay F; Laguerre B; Peyronnet B; Mathieu R; Verhoest G; Bensalah K; Leroy X; Aubert S; Vermaut C; Escande F; Verkarre V; Compérat E; Ambrosetti D; Pedeutour F; Belaud-Rotureau MA; Rioux-Leclercq N;
    Histopathology; 2022 Aug; 81(2):228-238. PubMed ID: 35562857
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Histological and molecular characterization of TFEB-rearranged renal cell carcinomas.
    Wyvekens N; Rechsteiner M; Fritz C; Wagner U; Tchinda J; Wenzel C; Kuithan F; Horn LC; Moch H
    Virchows Arch; 2019 May; 474(5):625-631. PubMed ID: 30706129
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SFPQ/PSF-TFE3 renal cell carcinoma: a clinicopathologic study emphasizing extended morphology and reviewing the differences between SFPQ-TFE3 RCC and the corresponding mesenchymal neoplasm despite an identical gene fusion.
    Wang XT; Xia QY; Ni H; Ye SB; Li R; Wang X; Shi SS; Zhou XJ; Rao Q
    Hum Pathol; 2017 May; 63():190-200. PubMed ID: 28315422
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential expression of cathepsin K in neoplasms harboring TFE3 gene fusions.
    Martignoni G; Gobbo S; Camparo P; Brunelli M; Munari E; Segala D; Pea M; Bonetti F; Illei PB; Netto GJ; Ladanyi M; Chilosi M; Argani P
    Mod Pathol; 2011 Oct; 24(10):1313-9. PubMed ID: 21602817
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sclerosing TFEB-rearrangement renal cell carcinoma: a recurring histologic pattern.
    Williamson SR; Eble JN; Palanisamy N
    Hum Pathol; 2017 Apr; 62():175-179. PubMed ID: 27864122
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Xp11 Translocation Renal Cell Carcinomas (RCCs) With RBM10-TFE3 Gene Fusion Demonstrating Melanotic Features and Overlapping Morphology With t(6;11) RCC: Interest and Diagnostic Pitfall in Detecting a Paracentric Inversion of TFE3.
    Xia QY; Wang XT; Zhan XM; Tan X; Chen H; Liu Y; Shi SS; Wang X; Wei X; Ye SB; Li R; Ma HH; Lu ZF; Zhou XJ; Rao Q
    Am J Surg Pathol; 2017 May; 41(5):663-676. PubMed ID: 28288037
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Renal epithelioid angiomyolipomas overexpress TFE3 and the TFE3-regulated gene TRIM63 in the absence of TFE3 rearrangement.
    Collins K; Bridge JA; Mehra R; Mannan R; Dickson BC; Lotan TL; Idrees MT; Ulbright TM; Acosta AM
    Virchows Arch; 2024 Sep; 485(3):471-478. PubMed ID: 38971946
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Renal cell carcinomas with t(6;11)(p21;q12) presenting with tubulocystic renal cell carcinoma-like features.
    Rao Q; Zhang XM; Tu P; Xia QY; Shen Q; Zhou XJ; Shi QL
    Int J Clin Exp Pathol; 2013; 6(7):1452-7. PubMed ID: 23826432
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Alpha gene upregulates TFEB expression in renal cell carcinoma with t(6;11) translocation, which promotes cell canceration.
    Zhan HQ; Li ST; Shu Y; Liu MM; Qin R; Li YL; Gan L
    Int J Oncol; 2018 Mar; 52(3):933-944. PubMed ID: 29328409
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PSF/SFPQ is a very common gene fusion partner in TFE3 rearrangement-associated perivascular epithelioid cell tumors (PEComas) and melanotic Xp11 translocation renal cancers: clinicopathologic, immunohistochemical, and molecular characteristics suggesting classification as a distinct entity.
    Rao Q; Shen Q; Xia QY; Wang ZY; Liu B; Shi SS; Shi QL; Yin HL; Wu B; Ye SB; Li L; Chen JY; Pan MH; Li Q; Li R; Wang X; Zhang RS; Yu B; Ma HH; Lu ZF; Zhou XJ
    Am J Surg Pathol; 2015 Sep; 39(9):1181-96. PubMed ID: 26274027
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MiT family translocation renal cell carcinoma.
    Argani P
    Semin Diagn Pathol; 2015 Mar; 32(2):103-13. PubMed ID: 25758327
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Aggressive TFEB-rearranged renal cell carcinoma mimicking chromophobe and clear cell renal cell carcinoma.
    Kojima F; Kuroda N; Matsuzaki I; Miyai H; Hara I; Murata SI; Hes O
    Pathol Int; 2019 Jan; 69(1):51-53. PubMed ID: 30620430
    [No Abstract]   [Full Text] [Related]  

  • 33. [The translocation carcinoma: A pediatric renal tumor also in adults].
    Bruder E; Moch H
    Pathologe; 2016 Mar; 37(2):159-65. PubMed ID: 26972595
    [TBL] [Abstract][Full Text] [Related]  

  • 34. TFEB Rearranged Renal Cell Carcinoma: Pathological and Molecular Characterization of 10 Cases, with Novel Clinical Implications: A Single Center 10-Year Experience.
    Wang AX; Tian T; Liu LB; Yang F; He HY; Zhou LQ
    Biomedicines; 2023 Jan; 11(2):. PubMed ID: 36830782
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comprehensive study of three novel cases of TFEB-amplified renal cell carcinoma and review of the literature: Evidence for a specific entity with poor outcome.
    Mendel L; Ambrosetti D; Bodokh Y; Ngo-Mai M; Durand M; Simbsler-Michel C; Delhorbe M; Amiel J; Pedeutour F
    Genes Chromosomes Cancer; 2018 Mar; 57(3):99-113. PubMed ID: 29127730
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cloning of an Alpha-TFEB fusion in renal tumors harboring the t(6;11)(p21;q13) chromosome translocation.
    Davis IJ; Hsi BL; Arroyo JD; Vargas SO; Yeh YA; Motyckova G; Valencia P; Perez-Atayde AR; Argani P; Ladanyi M; Fletcher JA; Fisher DE
    Proc Natl Acad Sci U S A; 2003 May; 100(10):6051-6. PubMed ID: 12719541
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TFEB Expression Profiling in Renal Cell Carcinomas: Clinicopathologic Correlations.
    Gupta S; Argani P; Jungbluth AA; Chen YB; Tickoo SK; Fine SW; Gopalan A; Al-Ahmadie HA; Sirintrapun SJ; Sanchez A; Hakimi AA; Mcfarlane T; Salazar PA; Williamson SR; Skala SL; Mehra R; Hes O; Antonescu CR; Ladanyi M; Arcila ME; Reuter VE
    Am J Surg Pathol; 2019 Nov; 43(11):1445-1461. PubMed ID: 31600176
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [2022 WHO classification of renal cell carcinomas: Focus on papillary renal cell carcinoma].
    Bellal S; Kammerer-Jacquet SF; Rioux-Leclercq N;
    Ann Pathol; 2024 Sep; 44(5):314-322. PubMed ID: 38729793
    [TBL] [Abstract][Full Text] [Related]  

  • 39. TFEB-VEGFA (6p21.1) co-amplified renal cell carcinoma: a distinct entity with potential implications for clinical management.
    Gupta S; Johnson SH; Vasmatzis G; Porath B; Rustin JG; Rao P; Costello BA; Leibovich BC; Thompson RH; Cheville JC; Sukov WR
    Mod Pathol; 2017 Jul; 30(7):998-1012. PubMed ID: 28338654
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diverse fusion patterns and heterogeneous clinicopathologic features of renal cell carcinoma with t(6;11) translocation.
    Inamura K; Fujiwara M; Togashi Y; Nomura K; Mukai H; Fujii Y; Yamamoto S; Yonese J; Fukui I; Ishikawa Y
    Am J Surg Pathol; 2012 Jan; 36(1):35-42. PubMed ID: 22173116
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.